Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Navamedic ASA
N1ANavamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson's disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway. Address: Henrik Ibsensgate 100, Oslo, Norway, 0255
Analytics
WallStreetin tavoitehinta
514.44 NOKP/E-suhde
21.8571Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut N1A
Osinkoanalytiikka N1A
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria N1A
Osakkeen arvostus N1A
Talousasiat N1A
Tuloksia | 2019 | Dynamiikka |